Review Article Open Access
Volume 2 | Issue 4 | DOI: https://doi.org/10.33696/cancerimmunol.2.029

Ovarian Function Suppression Plus Aromatase Inhibitors or Tamoxifen in Premenopausal HR-positive Breast Cancer

  • 1Dalian University, Dalian, 116622, China
  • 2Department of Breast and Thyroid Surgery , Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, China
+ Affiliations - Affiliations

Corresponding Author

Dianlong Zhang, zdldoctor@163.com

Received Date: July 27, 2020

Accepted Date: October 05, 2020


Adjuvant endocrine therapy for premenopausal hormone receptor (HR) positive breast cancer is a hot issue in recent years. Endocrine therapy for premenopausal HR-positive breast cancer includes selective estrogen receptor modulators (SERM, such as tamoxifen (TAM)), ovarian function suppression (OFS, including surgery, radiation or drug castration), and ovarian function suppression combined with TAM, aromatase inhibitors (AIs) must be combined with ovarian suppression. AIs or TAM plus ovarian function suppression are currently recommended for premenopausal HR-positive breast cancer patients with a higher risk of recurrence. However, there is still more to be explored on whether there is a difference between TAM plus OFS and Ais plus OFS. This review focus on the differences in efficacy between TAM plus OFS and AIs plus OFS in premenopausal HR-positive breast cancer patients.


HR-positive breast cancer, Premenopausal, Adjuvant endocrine therapy, TAM, AIs, OFS

Author Information X